FY23 consensus $7.99. Sees FY23 revenue growth low single digit decline vs. prior view of ~2% increase, consensus $46.56B. Cites lower than expected revenue for Revlimid and Pomalyst.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol-Myers Squibb (NYSE:BMY) Tanks on Q2 Miss; Guidance Disappoints
- Bristol-Myers reports Q2 adjusted EPS $1.75, consensus $1.98
- Notable companies reporting before tomorrow’s open
- BMY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Immatics (NASDAQ:IMTX) Gains on Equity Infusion by Bristol-Myers Squibb (NYSE:BMY)